Corticosteroids in IgA nephropathy: Lessons from recent studies

Journal of the American Society of Nephrology

Volumn 28, Issue 1, 2017, Pages 25-33

  Coppo, Rosanna ^a  

^a REGINA MARGHERITA CHILDREN S HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT;

CORTICOSTEROID THERAPY; DIABETES MELLITUS; DRUG SAFETY; GASTROINTESTINAL HEMORRHAGE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; IMMUNOGLOBULIN A NEPHROPATHY; INTENSIVE CARE; KIDNEY FUNCTION; OBSERVATIONAL STUDY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RETROSPECTIVE STUDY; REVIEW; DECISION TREE; GLOMERULONEPHRITIS, IGA;

ADRENAL CORTEX HORMONES; DECISION TREES; GLOMERULONEPHRITIS, IGA; HUMANS; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENIN-ANGIOTENSIN SYSTEM;

EID: 85020906283     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2016060647     Document Type: Review

References (72)

1. Wyatt RJ, Julian BA: IgA nephropathy. N Engl J Med 368: 2402-2414, 2013
2. Roberts IS: Pathology of IgA nephropathy. Nat Rev Nephrol 10: 445-454, 2014
3. Coppo R, D'Amico G: Factors predicting progression of IgA nephropathies.J Nephrol 18: 503-512, 2005
4. Berthoux F, Mohey H, Laurent B, Mariat C, Afiani A, Thibaudin L: Predicting the risk for dialysis or death in IgA nephropathy. J Am Soc Nephrol 22: 752-761, 2011
5. Shima Y, Nakanishi K, Hama T, Mukaiyama H, Togawa H, Sako M, Kaito H, Nozu K, Tanaka R, Iijima K, Yoshikawa N: Spontaneous remission in children with IgA nephropathy. Pediatr Nephrol 28: 71-76, 2013
6. Gutiérrez E, Zamora I, Ballarín JA, Arce Y, Jiménez S, Quereda C, Olea T, Martínez-Ara J, Segarra A, Bernis C, García A, Goicoechea M, García de Vinuesa S, Rojas-Rivera J, Praga M; Grupo de Estudio de Enfermedades Glomerulares de la Sociedad Española de Nefrología (GLOSEN): Long-term outcomes of IgA nephropathy presenting with minimal or no proteinuria. J Am Soc Nephrol 23: 1753-1760, 2012
7. Lee H, Hwang JH, Paik JH, Ryu HJ, Kim DK, Chin HJ, Oh YK, Joo KW, LimCS, KimYS, Lee JP: Long-term prognosis of clinically early IgA nephropathy is not always favorable. BMC Nephrol 15: 94, 2014
8. Tang Z, Wu Y, Wang QW, Yu YS, Hu WX, Yao XD, Chen HP, Liu ZH, Li LS: Idiopathic IgA nephropathy with diffuse crescent formation. Am J Nephrol 22: 480-486, 2002
9. Suzuki H, Kiryluk K, Novak J, Moldoveanu Z, Herr AB, Renfrow MB, Wyatt RJ, Scolari F, Mestecky J, Gharavi AG, Julian BA: The pathophysiology of IgA nephropathy. J Am Soc Nephrol 22: 1795-1803, 2011
10. Moldoveanu Z, Wyatt RJ, Lee JY, TomanaM, Julian BA, Mestecky J, Huang WQ, Anreddy SR, Hall S, Hastings MC, Lau KK, Cook WJ, Novak J: Patients with IgA nephropathy have increased serum galactose-deficient IgA1 levels. Kidney Int 71: 1148-1154, 2007
11. Suzuki H, Fan R, Zhang Z, Brown R, Hall S, Julian BA, ChathamWW, Suzuki Y, Wyatt RJ, Moldoveanu Z, Lee JY, Robinson J, Tomana M, Tomino Y, Mestecky J, Novak J: Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgGantibodies with restricted heterogeneity. J Clin Invest 119: 1668-1677, 2009
12. Mestecky J, Raska M, Julian BA, Gharavi AG, Renfrow MB, Moldoveanu Z, Novak L, Matousovic K, Novak J: IgA nephropathy: Molecular mechanisms of the disease. Annu Rev Pathol 8: 217-240, 2013
13. Magistroni R, D'Agati VD, Appel GB, Kiryluk K: New developments in the genetics, pathogenesis, and therapy of IgA nephropathy. Kidney Int 88: 974-989, 2015
14. Hastings MC, Moldoveanu Z, Suzuki H, Berthoux F, Julian BA, Sanders JT, Renfrow MB, Novak J, Wyatt RJ: Biomarkers in IgA nephropathy: Relationship to pathogenetic hits. Expert Opin Med Diagn 7: 615-627, 2013
15. Coppo R: Biomarkers and targeted new therapies for IgA nephropathy [published online ahead of print June 20, 2016]. Pediatr Nephrol
16. Kobayashi Y, Fujii K, Hiki Y, Tateno S: Steroid therapy in IgA nephropathy: A prospective pilot study inmoderate proteinuric cases.QJ Med 61: 935-943, 1986
17. Kobayashi Y, Hiki Y, Fujii K, Kurokawa A, Kamiyama M, Tateno S: Effect of corticosteroids on renal function in progressive IgA nephropathy-long-term follow-up study. Nippon Jinzo Gakkai Shi 30: 1135-1142, 1988
18. Vaerman JP: The secretory immune system. Antibiot Chemother (1971) 39: 41-50, 1987
19. Russell MW, Reinholdt J, Kilian M: Antiinflammatory activity of human IgA antibodies and their Fab alpha fragments: Inhibition of IgG-mediated complement activation. Eur J Immunol 19: 2243-2249, 1989
20. Reterink TJ, SchroeijersWE, Es LA, DahaMR: Dimeric and polymeric IgA, but not monomeric IgA, enhance the production of IL-6 by human renal mesangial cells. Mediators Inflamm 5: 191-195, 1996
21. Coppo R, Amore A: Aberrant glycosylation in IgA nephropathy (IgAN). Kidney Int 65: 1544-1547, 2004
22. Leung JC, Tang SC, Chan LY, Chan WL, Lai KN: Synthesis of TNF-alpha by mesangial cells cultured with polymeric anionic IgA- role of MAPK and NF-kappaB. Nephrol Dial Transplant 23: 72-81, 2008
23. Lai AS, Lai KN: Molecular basis of IgA nephropathy. Curr Mol Med 5: 475-487, 2005
24. Yanagihara T, Brown R, Hall S, Moldoveanu Z, Goepfert A, Tomana M, Julian BA, Mestecky J, Novak J: In vitro-generated immune complexes containing galactosedeficient IgA1 stimulate proliferation of mesangial cells. Results Immunol 2: 166-172, 2012
25. Pabst O: New concepts in the generation and functions of IgA. Nat Rev Immunol 12: 821-832, 2012
26. Pozzi C, Bolasco PG, Fogazzi GB, Andrulli S, Altieri P, Ponticelli C, Locatelli F: Corticosteroids in IgA nephropathy: A randomised controlled trial. Lancet 353: 883-887, 1999
27. Manno C, Torres DD, Rossini M, Pesce F, Schena FP: Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy. Nephrol Dial Transplant 24: 3694-3701, 2009
28. Lv J, Zhang H, Chen Y, Li G, Jiang L, Singh AK, Wang H: Combination therapy of prednisone and ACE inhibitor versus ACEinhibitor therapy alone in patients with IgA nephropathy: A randomized controlled trial. Am J Kidney Dis 53: 26-32, 2009
29. Jafar TH, Stark PC, Schmid CH, Landa M, MaschioG, de Jong PE, deZeeuwD, Shahinfar S, Toto R, Levey AS; AIPRD Study Group: Progression of chronic kidney disease: The role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: A patient-level meta-analysis. Ann Intern Med 139: 244-252, 2003
30. Lai KN, Chan LY, Tang SC, Tsang AW, Li FF, Lam MF, Lui SL, Leung JC: Mesangial expression of angiotensin II receptor in IgA nephropathy and its regulation by polymeric IgA1. Kidney Int 66: 1403-1416, 2004
31. PragaM, Gutiérrez E, González E, Morales E, Hernández E: Treatment of IgA nephropathy with ACE inhibitors: A randomized and controlled trial. J Am Soc Nephrol 14: 1578-1583, 2003
32. Coppo R, Peruzzi L, Amore A, Piccoli A, Cochat P, Stone R, Kirschstein M, Linné T: IgACE: A placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria. J Am Soc Nephrol 18: 1880-1888, 2007
33. Li PK, Leung CB, Chow KM, Cheng YL, Fung SK, Mak SK, Tang AW, Wong TY, Yung CY, Yung JC, Yu AW, Szeto CC; HKVIN Study Group: Hong Kong study using valsartan in IgA nephropathy (HKVIN): A double-blind, randomized, placebo-controlled study. Am J Kidney Dis 47: 751-760, 2006
34. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group: KDIGOClinical PracticeGuideline for Glomerulonephritis. Immunoglobulin A nephropathy. Kidney Int Suppl 2: 139-274, 2012
35. Pozzi C, Andrulli S, Del Vecchio L, Melis P, Fogazzi GB, Altieri P, Ponticelli C, Locatelli F: Corticosteroid effectiveness in IgA nephropathy: Long-term results of a randomized, controlled trial. J Am Soc Nephrol 15: 157-163, 2004
36. Ballardie FW, Roberts IS: Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy. J Am Soc Nephrol 13: 142-148, 2002
37. Tumlin JA, Lohavichan V, Hennigar R: Crescentic, proliferative IgA nephropathy: Clinical and histological response to methylprednisolone and intravenous cyclophosphamide. Nephrol Dial Transplant 18: 1321-1329, 2003
38. Vecchio M, Bonerba B, Palmer SC, Craig JC, Ruospo M, Samuels JA, Molony DA, Schena FP, Strippoli GF: Immunosuppressive agents for treating IgA nephropathy. Cochrane Database Syst Rev 3: CD003965, 2015
39. Pozzi C, Andrulli S, Pani A, Scaini P, Del Vecchio L, Fogazzi G, Vogt B, De Cristofaro V, Allegri L, Cirami L, Procaccini AD, Locatelli F: Addition of azathioprine to corticosteroids does not benefit patients with IgA nephropathy. JAmSocNephrol 21: 1783-1790, 2010
40. Eitner F, Floege J: Glomerular disease: ACEIs with or without corticosteroids in IgA nephropathy? Nat RevNephrol 6: 252-254, 2010
41. Roberts IS, Cook HT, Troyanov S, Alpers CE, Amore A, Barratt J, Berthoux F, Bonsib S, Bruijn JA, Cattran DC, Coppo R, D'Agati V, D'Amico G, Emancipator S, Emma F, Feehally J, Ferrario F, Fervenza FC, Florquin S, Fogo A, Geddes CC, Groene HJ, Haas M, Herzenberg AM, Hill PA, Hogg RJ, Hsu SI, Jennette JC, Joh K, Julian BA, Kawamura T, Lai FM, Li LS, Li PK, Liu ZH, Mackinnon B, Mezzano S, Schena FP, Tomino Y, Walker PD, Wang H, Weening JJ, Yoshikawa N, Zhang H; Working Group of the International IgA Nephropathy Network and the Renal Pathology Society: The Oxford classification of IgA nephropathy: Pathology definitions, correlations, and reproducibility. Kidney Int 76: 546-556, 2009
42. Cattran DC, Coppo R, Cook HT, Feehally J, Roberts IS, Troyanov S, Alpers CE, Amore A, Barratt J, Berthoux F, Bonsib S, Bruijn JA, D'Agati V, D'Amico G, Emancipator S, Emma F, Ferrario F, Fervenza FC, Florquin S, Fogo A, Geddes CC, Groene HJ, Haas M, Herzenberg AM, Hill PA, Hogg RJ, Hsu SI, Jennette JC, Joh K, Julian BA, Kawamura T, Lai FM, Leung CB, Li LS, Li PK, Liu ZH, Mackinnon B, Mezzano S, Schena FP, Tomino Y, Walker PD, Wang H, Weening JJ, Yoshikawa N, Zhang H; Working Group of the International IgA Nephropathy Network and the Renal Pathology Society: TheOxford classification of IgA nephropathy: Rationale, clinicopathological correlations, and classification. Kidney Int 76: 534-545, 2009
43. Herzenberg AM, Fogo AB, Reich HN, Troyanov S, Bavbek N, Massat AE, Hunley TE, Hladunewich MA, Julian BA, Fervenza FC, Cattran DC: Validation of the Oxford classification of IgA nephropathy. Kidney Int 80: 310-317, 2011
44. Yau T, Korbet SM, Schwartz MM, Cimbaluk DJ: The Oxford classification of IgA nephropathy: A retrospective analysis. Am J Nephrol 34: 435-444, 2011
45. Alamartine E, Sauron C, Laurent B, Sury A, Seffert A, Mariat C: The use of the Oxford classification of IgA nephropathy to predict renal survival. Clin J Am Soc Nephrol 6: 2384-2388, 2011
46. Zeng CH, LeW, Ni Z, ZhangM, Miao L, Luo P, Wang R, Lv Z, Chen J, Tian J, Chen N, Pan X, Fu P, Hu Z, Wang L, Fan Q, Zheng H, Zhang D, Wang Y, Huo Y, Lin H, Chen S, Sun S, Wang Y, Liu Z, Liu D, Ma L, Pan T, Zhang A, Jiang X, Xing C, Sun B, Zhou Q, Tang W, Liu F, Liu Y, Liang S, Xu F, Huang Q, Shen H, Wang J, Shyr Y, Phillips S, Troyanov S, Fogo A, Liu ZH: A multicenter application and evaluation of the oxford classification of IgA nephropathy in adult chinese patients. Am J Kidney Dis 60: 812-820, 2012
47. Katafuchi R, Ninomiya T, Nagata M, Mitsuiki K, Hirakata H: Validation study of oxford classification of IgA nephropathy: The significance of extracapillary proliferation. Clin J Am Soc Nephrol 6: 2806-2813, 2011
48. Shi SF, Wang SX, Jiang L, Lv JC, Liu LJ, Chen YQ, Zhu SN, Liu G, Zou WZ, Zhang H, Wang HY: Pathologic predictors of renal outcome and therapeutic efficacy in IgA nephropathy: Validation of the Oxford classification. Clin J Am Soc Nephrol 6: 2175-2184, 2011
49. Lv J, Shi S, Xu D, Zhang H, Troyanov S, Cattran DC, Wang H: Evaluation of the Oxford Classification of IgA nephropathy: A systematic review and meta-analysis. Am J Kidney Dis 62: 891-899, 2013
50. Coppo R, Troyanov S, Bellur S, Cattran D, Cook HT, Feehally J, Roberts IS, Morando L, Camilla R, Tesar V, Lunberg S, Gesualdo L, Emma F, Rollino C, Amore A, Praga M, Feriozzi S, Segoloni G, Pani A, Cancarini G, Durlik M, Moggia E, Mazzucco G, Giannakakis C, Honsova E, Sundelin BB, Di Palma AM, Ferrario F, Gutierrez E, Asunis AM, Barratt J, Tardanico R, Perkowska-Ptasinska A; VALIGA study of the ERA-EDTA Immunonephrology Working Group: Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments. Kidney Int 86: 828-836, 2014
51. Tesar V, Troyanov S, Bellur S, Verhave JC, Cook HT, Feehally J, Roberts IS, Cattran D, Coppo R; VALIGA study of the ERA-EDTA Immunonephrology Working Group: Corticosteroids in IgA nephropathy: A retrospective analysis from the VALIGA Study. J Am Soc Nephrol 26: 2248-2258, 2015
52. Rauen T, Eitner F, Fitzner C, Sommerer C, Zeier M, Otte B, Panzer U, Peters H, Benck U, Mertens PR, Kuhlmann U, Witzke O, Gross O, Vielhauer V, Mann JF, Hilgers RD, Floege J; STOP-IgAN Investigators: Intensive supportive care plus immunosuppression in IgA nephropathy. N Engl J Med 373: 2225-2236, 2015
53. Ruggenenti P, Perticucci E, Cravedi P, Gambara V, Costantini M, Sharma SK, Perna A, Remuzzi G: Role of remission clinics in the longitudinal treatment of CKD. J Am Soc Nephrol 19: 1213-1224, 2008
54. Reich HN, Troyanov S, Scholey JW, Cattran DC; Toronto Glomerulonephritis Registry: Remission of proteinuria improves prognosis in IgA nephropathy. J Am Soc Nephrol 18: 3177-3183, 2007
55. Nam KH, Kie JH, Lee MJ, Chang TI, Kang EW, Kim DW, Lim BJ, Park JT, Kwon YE, Kim YL, Park KS, An SY, Oh HJ, Yoo TH, Kang SW, Choi KH, Jeong HJ, Han DS, Han SH: Optimal proteinuria target for renoprotection in patients with IgA nephropathy. PLoS One 9: e101935, 2014
56. Inker LA, Mondal H, Greene T, Masaschi T, Locatelli F, Schena FP, Katafuchi R, Appel GB, Maes BD, Li PK, Praga M, Del Vecchio L, Andrulli S, Manno C, Gutierrez E, Mercer A, Carroll KJ, Schmid CH, Levey AS: Early change in urine protein as a surrogate end point in studies of IgA nephropathy: An individual-patient meta-analysis [published online ahead of print March 29, 2016]. Am J Kidney Dis doi:10.1053/j.ajkd.2016.02.042
57. Sarcina C, Tinelli C, Ferrario F, Pani A, De Silvestri A, Scaini P, Del Vecchio L, Alberghini E, Buzzi L, Baragetti I, Pozzi C: Changes in proteinuria and side effects of corticosteroids alone or in combination with azathioprine at different stages of IgA nephropathy. Clin J Am Soc Nephrol 11: 973-981, 2016
58. Ayoub I, Hebert L, Rovin BH: Intensive supportive care plus immunosuppression in IgA nephropathy. N Engl J Med 374: 991-992, 2016
59. Lv J, Xu D, Perkovic V, Ma X, Johnson DW, Woodward M, Levin A, Zhang H, Wang H; TESTING Study Group: Corticosteroid therapy in IgA nephropathy. J Am Soc Nephrol 23: 1108-1116, 2012
60. Pozzi C, Andrulli S, Pani A, Scaini P, Roccatello D, Fogazzi G, Pecchini P, Rustichelli R, Finocchiaro P, Del Vecchio L, Locatelli F: IgA nephropathy with severe chronic renal failure:Arandomized controlled trial of corticosteroids and azathioprine. J Nephrol 26: 86-93, 2013
61. Barbour SJ, Espino-Hernandez G, Reich HN, Coppo R, Roberts IS, Feehally J, Herzenberg AM, Cattran DC; Oxford Derivation, North American Validation and VALIGA Consortia; Oxford Derivation North American Validation and VALIGA Consortia: The MEST score provides earlier risk prediction in IgA nephropathy. Kidney Int 89: 167-175, 2016
62. Bartosik LP, Lajoie G, Sugar L, Cattran DC: Predicting progression in IgA nephropathy. AmJ Kidney Dis 38: 728-735, 2001
63. Coppo R: The intestine-renal connection in IgA nephropathy. Nephrol Dial Transplant 30: 360-366, 2015
64. Smerud HK, Bárány P, Lindström K, Fernström A, Sandell A, Pahlsson P, Fellström B: New treatment for IgA nephropathy: Enteric budesonide targeted to the ileocecal region ameliorates proteinuria. Nephrol Dial Transplant 26: 3237-3242, 2011
65. Papista C, Lechner S, Ben Mkaddem S, LeStang MB, Abbad L, Bex-Coudrat J, Pillebout E, Chemouny JM, Jablonski M, Flamant M, Daugas E, Vrtovsnik F, Yiangou M, Berthelot L, Monteiro RC: Gluten exacerbates IgA nephropathy in humanized mice through gliadin-CD89 interaction. Kidney Int 88: 276-285, 2015
66. McCarthy DD, Kujawa J, Wilson C, Papandile A, Poreci U, Porfilio EA, Ward L, Lawson MA, Macpherson AJ, McCoy KD, Pei Y, Novak L, Lee JY, Julian BA, Novak J, Ranger A, Gommerman JL, Browning JL: Mice overexpressing BAFF develop a commensal flora-dependent, IgA-associated nephropathy. J Clin Invest 121: 3991-4002, 2011
67. Kiryluk K, Li Y, Scolari F, Sanna-Cherchi S, Choi M, Verbitsky M, Fasel D, Lata S, Prakash S, Shapiro S, Fischman C, Snyder HJ, Appel G, Izzi C, Viola BF, Dallera N, Del Vecchio L, Barlassina C, Salvi E, Bertinetto FE, Amoroso A, Savoldi S, Rocchietti M, Amore A, Peruzzi L, Coppo R, Salvadori M, Ravani P, Magistroni R, Ghiggeri GM, Caridi G, Bodria M, Lugani F, Allegri L, Delsante M, MaioranaM, MagnanoA, FrascaG, Boer E, Boscutti G, Ponticelli C, Mignani R, Marcantoni C, Di Landro D, Santoro D, Pani A, Polci R, Feriozzi S, Chicca S, Galliani M, Gigante M, Gesualdo L, Zamboli P, Battaglia GG, Garozzo M, Maixnerová D, Tesar V, Eitner F, Rauen T, Floege J, Kovacs T, Nagy J, Mucha K, Pączek L, Zaniew M, Mizerska-Wasiak M, Roszkowska-Blaim M, Pawlaczyk K, Gale D, Barratt J, Thibaudin L, Berthoux F, Canaud G, Boland A, MetzgerM, Panzer U, Suzuki H, Goto S, Narita I, Caliskan Y, Xie J, Hou P, Chen N, ZhangH, Wyatt RJ, Novak J, Julian BA, Feehally J, Stengel B, Cusi D, Lifton RP, Gharavi AG: Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens. Nat Genet 46: 1187-1196, 2014
68. Lai KN, Leung JC, Chan LY, Saleem MA, Mathieson PW, Tam KY, Xiao J, Lai FM, Tang SC: Podocyte injury induced by mesangialderived cytokines in IgA nephropathy. Nephrol Dial Transplant 24: 62-72, 2009
69. Coppo R, Fonsato V, Balegno S, Ricotti E, Loiacono E, Camilla R, Peruzzi L, Amore A, Bussolati B, Camussi G: Aberrantly glycosylated IgA1 induces mesangial cells to produce platelet-activating factor that mediates nephrin loss in cultured podocytes. Kidney Int 77: 417-427, 2010
70. Cravedi P, Remuzzi G: Pathophysiology of proteinuria and its value as an outcome measure in chronic kidney disease. Br J Clin Pharmacol 76: 516-523, 2013
71. Woo KT, Lau YK: Proteinuria: Clinical significance and basis for therapy. Singapore Med J 42: 385-389, 2001
72. Coppo R: Is a legacy effect possible in IgA nephropathy? Nephrol Dial Transplant 28: 1657-1662, 2013